Investigation of the expression levels of CPEB4, APC, TRIP13, EIF2S3, EIF4A1, IFNg, PIK3CA and CTNNB1 genes in different stage colorectal tumors


Journal

Turkish journal of medical sciences
ISSN: 1303-6165
Titre abrégé: Turk J Med Sci
Pays: Turkey
ID NLM: 9441758

Informations de publication

Date de publication:
30 04 2021
Historique:
received: 02 10 2020
accepted: 24 11 2020
entrez: 25 11 2020
pubmed: 26 11 2020
medline: 15 12 2021
Statut: epublish

Résumé

The aim of the study is to assess expression levels of CPEB4, APC, TRIP13, EIF2S3, EIF4A1, IFNg, PIK3CA and CTNNB1 genes in tumors and peripheral bloods of colorectal cancer patients in stages I–IV. The mRNA levels of the genes were determined in tumor tissues and peripheral blood samples of 45 colorectal cancer patients and colon tissues and peripheral blood samples of 5 healthy individuals. Real-time polymerase chain reaction method was used for the analysis. The mRNA level of the CPEB4 gene was significantly downregulated in colorectal tumor tissues and was upregulated in the peripheral blood of colorectal cancer patients relative to the controls (P < 0.05). APC mRNA level was significantly downregulated in tissues and upregulated in the peripheral blood (P < 0.05). TRIP13 mRNA level was upregulated in peripheral blood and also significantly upregulated in colorectal tumor tissues (P < 0.05). EIF2S3 mRNA level was upregulated in tissues and also significantly upregulated in peripheral blood (P < 0.05). PIK3CA mRNA level was downregulated in tissues and upregulated in peripheral blood. EIF4A1 mRNA level was downregulated in tissues and significantly upregulated in peripheral blood (P < 0.05). CTNNB1 mRNA level was downregulated in tissues and upregulated in peripheral blood. IFNg mRNA level was upregulated in both colorectal cancer tumor tissues and peripheral blood. TRIP13 and CPEB4 mRNA up regulation in the peripheral blood of patients with colorectal cancer may be a potential target for early stage diagnosis. In addition to this evaluation, although there is not much study on EIF2S3 and EIF4A1 mRNA changes in cases with colorectal cancer, upregulation in peripheral blood draws attention in our study. These data will shed light on the new comprehensive studies.

Sections du résumé

Background/aim
The aim of the study is to assess expression levels of CPEB4, APC, TRIP13, EIF2S3, EIF4A1, IFNg, PIK3CA and CTNNB1 genes in tumors and peripheral bloods of colorectal cancer patients in stages I–IV.
Materials and methods
The mRNA levels of the genes were determined in tumor tissues and peripheral blood samples of 45 colorectal cancer patients and colon tissues and peripheral blood samples of 5 healthy individuals. Real-time polymerase chain reaction method was used for the analysis.
Results
The mRNA level of the CPEB4 gene was significantly downregulated in colorectal tumor tissues and was upregulated in the peripheral blood of colorectal cancer patients relative to the controls (P < 0.05). APC mRNA level was significantly downregulated in tissues and upregulated in the peripheral blood (P < 0.05). TRIP13 mRNA level was upregulated in peripheral blood and also significantly upregulated in colorectal tumor tissues (P < 0.05). EIF2S3 mRNA level was upregulated in tissues and also significantly upregulated in peripheral blood (P < 0.05). PIK3CA mRNA level was downregulated in tissues and upregulated in peripheral blood. EIF4A1 mRNA level was downregulated in tissues and significantly upregulated in peripheral blood (P < 0.05). CTNNB1 mRNA level was downregulated in tissues and upregulated in peripheral blood. IFNg mRNA level was upregulated in both colorectal cancer tumor tissues and peripheral blood.
Conclusion
TRIP13 and CPEB4 mRNA up regulation in the peripheral blood of patients with colorectal cancer may be a potential target for early stage diagnosis. In addition to this evaluation, although there is not much study on EIF2S3 and EIF4A1 mRNA changes in cases with colorectal cancer, upregulation in peripheral blood draws attention in our study. These data will shed light on the new comprehensive studies.

Identifiants

pubmed: 33237662
doi: 10.3906/sag-2010-18
pmc: PMC8208508
doi:

Substances chimiques

Biomarkers 0
Biomarkers, Tumor 0
CPEB4 protein, human 0
CTNNB1 protein, human 0
Cell Cycle Proteins 0
IFNG protein, human 0
RNA, Messenger 0
RNA-Binding Proteins 0
beta Catenin 0
Interferon-gamma 82115-62-6
Class I Phosphatidylinositol 3-Kinases EC 2.7.1.137
PIK3CA protein, human EC 2.7.1.137
ATPases Associated with Diverse Cellular Activities EC 3.6.4.-
TRIP13 protein, human EC 3.6.4.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

661-674

Informations de copyright

This work is licensed under a Creative Commons Attribution 4.0 International License.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Références

Cancer Res. 2010 Mar 15;70(6):2406-14
pubmed: 20215514
Front Immunol. 2017 Jul 26;8:878
pubmed: 28798748
Transl Oncol. 2012 Apr;5(2):72-6
pubmed: 22496922
Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9309-14
pubmed: 15184677
Medicine (Baltimore). 2015 Jul;94(27):e979
pubmed: 26166131
Int J Cancer. 2013 Oct 15;133(8):1914-25
pubmed: 23494461
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
PLoS One. 2012;7(11):e48958
pubmed: 23145039
Mol Cell Biol. 1996 Aug;16(8):4088-94
pubmed: 8754807
Cell Death Dis. 2018 Mar 14;9(3):402
pubmed: 29540729
Front Oncol. 2014 Mar 03;4:35
pubmed: 24624362
Nucleic Acids Res. 2002 May 1;30(9):e36
pubmed: 11972351
Cancer Res. 1997 Oct 15;57(20):4624-30
pubmed: 9377578
Front Oncol. 2017 Jul 26;7:158
pubmed: 28798901
PLoS One. 2016 May 09;11(5):e0155025
pubmed: 27158894
Biochem Biophys Res Commun. 2017 Jul 22;489(2):135-141
pubmed: 28536077
Int J Colorectal Dis. 2005 Sep;20(5):391-402
pubmed: 15883783
Oncogene. 2002 Jun 13;21(26):4120-8
pubmed: 12037668
Chromosoma. 2015 Sep;124(3):333-9
pubmed: 25895724
Diagn Pathol. 2015 Jul 25;10:127
pubmed: 26209100
Cancer Res. 2004 Nov 1;64(21):7678-81
pubmed: 15520168
Gastroenterology. 2002 Sep;123(3):751-63
pubmed: 12198702
J Allergy Clin Immunol. 2011 Mar;127(3):701-21.e1-70
pubmed: 21377040
World J Gastroenterol. 2014 Oct 21;20(39):14463-71
pubmed: 25339833
Nat Rev Cancer. 2002 Jul;2(7):489-501
pubmed: 12094235
Arch Med Sci. 2014 Feb 24;10(1):1-9
pubmed: 24701207
Int J Cancer. 2012 Oct 1;131(7):1649-58
pubmed: 21607946
Virchows Arch. 2017 Jan;470(1):37-45
pubmed: 27771769
Oncotarget. 2017 Apr 18;8(16):26718-26731
pubmed: 28157697
Cytokine Growth Factor Rev. 2000 Dec;11(4):273-82
pubmed: 10959075
Hum Mol Genet. 2001 Apr;10(7):721-33
pubmed: 11257105
Nat Med. 2011 Dec 04;18(1):83-90
pubmed: 22138752
Prog Nucleic Acid Res Mol Biol. 2002;72:307-31
pubmed: 12206455
Oncogene. 2002 Jul 18;21(31):4855-62
pubmed: 12101425
Med Hypotheses. 2013 Nov;81(5):875-7
pubmed: 24045092
Dis Colon Rectum. 2004 Feb;47(2):141-52
pubmed: 15043283
Science. 2004 Apr 23;304(5670):554
pubmed: 15016963
J Invest Dermatol. 2012 Aug;132(8):2050-9
pubmed: 22513784
Oncotarget. 2017 Apr 11;8(15):25469-25481
pubmed: 28424416
Curr Opin Genet Dev. 1999 Feb;9(1):15-21
pubmed: 10072352
Oncol Rep. 2006 Oct;16(4):747-54
pubmed: 16969489
Oncotarget. 2016 Aug 2;7(31):50582-50595
pubmed: 27418131
Nat Genet. 2006 Sep;38(9):1043-8
pubmed: 16921376
Am J Med Genet A. 2016 Nov;170(11):2927-2933
pubmed: 27333055
Biochem Biophys Res Commun. 2015 Oct 16;466(2):206-13
pubmed: 26361147
Tumour Biol. 2017 Apr;39(4):1010428317694538
pubmed: 28381179
Clin Neurol Neurosurg. 2018 Jun;169:92-97
pubmed: 29642043
J Exp Clin Cancer Res. 2018 Aug 29;37(1):203
pubmed: 30157906
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
EMBO J. 1995 Nov 15;14(22):5618-25
pubmed: 8521819
Nat Commun. 2014 Jul 31;5:4527
pubmed: 25078033
Comput Struct Biotechnol J. 2019 Jun 22;17:854-861
pubmed: 31321001
Oncol Lett. 2016 Dec;12(6):5240-5246
pubmed: 28105232
Cancer Res. 2001 May 1;61(9):3544-9
pubmed: 11325815
IET Syst Biol. 2015 Dec;9(6):294-302
pubmed: 26577164
Carcinogenesis. 2009 Sep;30(9):1469-74
pubmed: 19372138

Auteurs

Zafer Söylemez (Z)

Department of Medical Biology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey

Evrim Suna Arıkan (ES)

Department of Medical Biology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey

Mustafa Solak (M)

Department of Medical Genetic, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey

Yüksel Arıkan (Y)

General Surgery Department, Park Hayat Hospital, Afyonkarahisar, Turkey

Çiğdem Tokyol (Ç)

Department of Patology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey

Hüseyin Şeker (H)

School of Computing and Digital Technologies, Staffordshire University, Stroke-on-Trent, United Kingdom

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH